Publikationsserver
Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide
Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Philipps-Universität Marburg
2022
|
| 主題: | |
| オンライン･アクセス: | PDFフルテキスト |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
PDFフルテキスト| 請求記号: |
urn:nbn:de:hebis:04-es2023-00588 |
|---|---|
| 出版日付: |
2023-05-16 |
| ソース: |
Erstveröffentlichung: Otte, K.; Zhao, K.; Braun, M.; Neubauer, A.; Raifer, H.; Helmprobst, F.; Barrera, F.O.; Nimsky, C.; Bartsch, J.W.; Rusch, T. Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide. Biomedicines 2022, 10, 2145. https://doi.org/10.3390/biomedicines10092145 |
| Downloads: |
21 (2024), 44 (2023) |
| Lizenz: |
https://creativecommons.org/licenses/by/4.0 |
| アクセスURL: |
https://archiv.ub.uni-marburg.de/es/2023/0058 https://doi.org/10.3390/biomedicines10092145 |